{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifcsp6oy5hyro3b2a2uv7g4g5v7yw3bjreznnk2qrb34fwvlzziby",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mna32lqh3ee2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiev3j3l3j4alwiko23aqzd6xqu35ah5hhgl2lw6jylpti34em7dc4"
    },
    "mimeType": "image/jpeg",
    "size": 32914
  },
  "path": "/news/2026-06-rason-inhibitor-median-survival-patients.html",
  "publishedAt": "2026-06-01T08:00:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized Phase III RASolute 302 trial comparing daraxonrasib to chemotherapy as second-line therapy for patients with metastatic pancreatic cancer.",
  "title": "RAS(ON) inhibitor doubles median overall survival in patients with metastatic pancreatic cancer"
}